COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 1031: Articles 10301-10310  | Next

Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2
Yang, X., Dickmander, R. J., Bayati, A., Taft-Benz, S. A., Smith, J. L., Brown, J. W., Lenarcic, E. M., Yount, B. L., Chang, E., Axtman, A. D., Baric, R. S., Heise, M. T., McPherson, P. S., Moorman, N. J., Willson, T. M.
10.1101/2022.01.03.474779 — Posted: 2022-01-04
A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
Yuan, T. Z., Lucas, C., Monteiro, V. S., Iwasaki, A., Yang, M. L., Nepita, H. F., Lujan Hernandez, A. G., Taft, J. M., Frei, L., Reddy, S. T., Weber, C., Malobisky, K. P., Mesquita, R., Sato, A.
10.1101/2022.01.04.474803 — Posted: 2022-01-04
Maternal cytokine response after SARS-CoV-2 infection during pregnancy
Gigase, F. A. J., Molenaar, N. M., Missall, R. D., Rommel, A.-S., Lieb, W., Ibroci, E., Ohrn, S., Lynch, J., Krammer, F., Brody, R., Jessel, R. H., Sperling, R. S., Lesseur, C., Callipari, F., Galang, R. R., Snead, M. C., Janevic, T., Stone, J., Howell, E. A., Chen, J., Pop, V. J. M., Dolan, S. M., Bergink, V., De Witte, L. D.
10.1101/2022.01.04.474908 — Posted: 2022-01-04
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
Bojkova, D., Widera, M., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J. N.
10.1101/2022.01.03.474773 — Posted: 2022-01-04
The SARS-CoV-2 infection in Thailand: analysis of spike variants complemented by protein structure insights
Ittisoponpisan, S., Yahangkiakan, S., Sternberg, M. J. E., David, A.
10.1101/2022.01.01.474713 — Posted: 2022-01-04
Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial
AlKaabi, N., Yang, Y. K., Zhang, J., Xu, K., Liang, Y., Kang, Y., Su, J. G., Yang, T., Hussein, S., ElDein, M. S., Shao, S., Yang, S. S., Lei, W., Gao, X. J., Jiang, Z., Wang, H., Li, M., Mekki, H. M., Zaher, W., Mahmoud, S., Zhang, X., Qu, C., Liu, D. Y., Zhang, J., Yang, M., ElTantawy, I., Xiao, P., Wang, Z. N., Yin, J. L., Mao, X. Y., Zhang, J., Liu, N., Shen, F. J., Qu, L., Zhang, Y. T., Yang, X. M., Wu, G., Li, Q. M.
10.1101/2021.12.29.21268499 — Posted: 2022-01-04
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
Valanparambil, R., Carlisle, J., Ahmed, R., Linderman, S., Akthar, A., Millett, R. L., Lai, L., Chang, A., McCook, A., Switchenko, J., Nasti, T., Saini, M., Andreas Wieland, A. W., Manning, K., Ellis, M., Moore, K., Foster, S., Floyd, K., Davis-Gardner, M., Viswanadh Edara, V., Patel, M., Steur, C., Nooka, A., Green, F., Johns, M., O Brein, F., Shanmugasundaram, U., Zarnitsyna, V., Ahmed, H., Nyhoff, L., Mantus, G., Garett, M., Edupuganti, S., Behra, M., Antia, R., Wrammert, J., Suthar, M., Dhodapkar, M., Ramalingam, S.
10.1101/2022.01.03.22268599 — Posted: 2022-01-03
Shielding individuals at high risk of COVID-19: a micro-simulation study
van Zandvoort, K., Favas, C., Checchi, F.
10.1101/2022.01.03.22268675 — Posted: 2022-01-03
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Willett, B. J., Grove, J., MacLean, O., Wilkie, C., Logan, N., De Lorenzo, G., Furnon, W., Scott, S., Manali, M., Szemiel, A., Ashraf, S., Vink, E., Harvey, W., Davis, C., Orton, R., Hughes, J., Holland, P., Silva, S. V., Pascall, D., Puxty, K., da Silva Filipe, A., Yebra, G., Shaaban, S., Holden, M. T. G., Pinto, R. M., Gunson, R., Templeton, K., Murcia, P., Patel, A., The COVID-19 DeplOyed VaccinE (DOVE) Investigators, , COVID-19 EVADE Cohort Study, , The COVID-19 Genomics UK (COG-UK) Consortium, , The G2P-UK National Virology Consortium, , Haughney, J., Robertson, D. L., Palmarini, M., Ray, S., Thomson, E. C.
10.1101/2022.01.03.21268111 — Posted: 2022-01-03 Discussion: Onsite | Offsite
Mapping the antigenic diversification of SARS-CoV-2
van der Straten, K., Guerra, D., van Gils, M., Bontjer, I., Caniels, T. G., van Willigen, H. D., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., Lavell, A., Appelman, B., Sikkens, J. J., Bomers, M., Han, A. X., Nichols, B. E., Prins, M., Vennema, H., Reusken, C., Eggink, D., de Jong, M., de Bree, G. J., Russell, C. A., Sanders, R. W.
10.1101/2022.01.03.21268582 — Posted: 2022-01-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).